Superparamagnetic Nanoparticles and RNAi-Mediated Gene Silencing: Evolving Class of Cancer Diagnostics and Therapeutics

Table 2

Development of siRNA in cancer therapy.

S. no. Cell Line	Target	Result	REF
(1) PC-3 and DU 145	hTERT	Downregulation of hTERT inhibited cell proliferation	[27]
(2) HT144	RRM2	Downregulation of RRM2 inhibited cell proliferation	[28]
(3) H1299 and MDA-MB-468	Ran,TPX2, SCD1	Reduced survival of human tumor cell lines	[29]
(4) H1299	PTTG	Decreasing PTTG expression reduced tumor growth in vivo and in vitro	[30]
(5) Panc-1, PCI-19, PAN-03-JCK, and so forth	S100A4	Knockdown of S100A4 suppressed cell growth, induced apoptosis, and decreased cell migration	[31]
(6) MDA-MB-231 and ZR751	uPA	Downregulation of decreased tumor invasion, angiogenesis, and growth	[32]
(7) A549 and H460	Nrf2	Silencing inhibited tumor growth, and increasing efficacy of chemotherapy	[33]
(8) Cx1, HCT8, HT29, HCT15, and so forth.	CDCA1 and KNTC2	Knockdown suppressed cell proliferation and induced apoptosis	[34]
(9) A549 PC9	Wild type p53 Surviving	Inhibition of wildtype p53 upregulated antiapoptotic survin expression. Inhibition of surviving with mutated p53 depressed cell proliferation	[35]
(10) Ten HNSCC cell lines from one nasal cavity cancer (RPMI12650)	IGF2	Upregulation acquired resistance for RDDP in human head and neck squamous cell carcinoma	[36]